MTIM
IMNM icon

Marathon Trading Investment Management’s Immunome IMNM Stock Holding History

Marathon Trading Investment Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,500
Closed -$580K – 341
2024
Q1 		$580K Buy
+23,500
New +$477K 0.04% 145

Other funds holding IMNM

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Marathon Trading Investment Management's IMNM Position: Q2 2024 in Review

Marathon Trading Investment Management sold out of Immunome (IMNM) in Q2 2024, closing a stake of 23,500 shares — an estimated $580K sold.

Marathon Trading Investment Management first reported a position in IMNM in Q1 2024 and held it in 1 quarter. The position peaked at $580K in Q1 2024. 113 funds tracked by Wall St. Rank hold IMNM as of Q2 2024.

  • Marathon Trading Investment Management reported no remaining Immunome position as of Q2 2024 after selling out during the quarter.
  • Marathon Trading Investment Management sold 23,500 Immunome shares in Q2 2024, an estimated $580K.
  • Marathon Trading Investment Management first reported a position in Immunome in Q1 2024 and held it in 1 quarter.
  • Marathon Trading Investment Management's Immunome position peaked at $580K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Immunome as of Q2 2024.

Based on Marathon Trading Investment Management's 13F filing for Q2 2024, filed 12 Aug 2024.